RBPJ

Across TCGA pan-cancer cohorts, RBPJ mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated RBPJ data layer compared with 28 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher RBPJ mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated RBPJ expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.

HNSC, PDAC, and CCRCC are the cancer types where RBPJ mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Tertile	II,III,IV	0.526	0.808	.005	29	view →
PDAC	OS	Tertile	All	0.423	0.616	.025	18	view →
CCRCC	DFS	Tertile	All	0.453	0.985	.004	13	view →
LSCC	DFS	Tertile	All	1.000	0.934	.024	4	view →
LUAD	DFS	Median	III,IV	0.409	0.941	.010	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

RBPJ–HNSC (DFS)

Open the HNSC breakdown →